CareLit · DOI-Nachweis · Pneumologie
Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis: Results of two 52-week, Phase III, randomized, placebo-controlled trials (INPULSIS™)
DOI 10.1055/s-0035-1544829
Bibliografische Angaben
Nachweis in CareLit
Autor:innenU Costabel, L Richeldi, RM du Bois, G Raghu, A Azuma, KK Brown, V Cottin, KR Flaherty, Y Inoue, DS Kim, M Kolb, PW Noble, M Selman, H Taniguchi, M Brun, M Girard, R Schlenker-Herceg, B Disse, HR Collard
ZeitschriftPneumologie
Ausgabe02/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. Methods: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 [NCT01335464] and INPULSIS-2 [NCT01335477]) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis (IPF). The…
Zitieren
Zitierempfehlung
U Costabel, L Richeldi, RM du Bois, G Raghu, A Azuma, KK Brown, V Cottin, KR Flaherty, Y Inoue, DS Kim, M Kolb, PW Noble, M Selman, H Taniguchi, M Brun, M Girard, R Schlenker-Herceg, B Disse, HR Collard (2015) Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis: Results of two 52-week, Phase III, randomized, placebo-controlled trials (INPULSIS™). Pneumologie (02). https://doi.org/10.1055/s-0035-1544829
Mit CareLit weiterarbeiten